Table 2.
Clinical data of the 7 patients with PTCL
| Number | Gender | Age (y) | IPI | AnnArbor | Pathologic subtypes | OS (months) | PFS (months) | Initial chemotherapy | Assessment of disease |
|---|---|---|---|---|---|---|---|---|---|
| C1 | Female | 61 | 5 | IV B | Enteropathy‐associated T‐cell lymphoma | 2 | 0 | 1 cycle of chidamide+CHOEP | PD |
| C3 | Male | 71 | 4 | IV B | Anaplastic large‐cell lymphoma, ALK‐ | 9 | 9 | 8 cycles of chidamide+CHOP | PR |
| C5 | Male | 34 | 0 | IE A | Subcutaneous panniculitis like T‐cell lymphoma | 18 | 18 | 8 cycles of chidamide+CHOP | CR |
| C6 | Male | 53 | 3 | IV B | Enteropathy‐associated T‐cell lymphoma | 12 | 11 | 8 cycles of CHOEP | PD |
| C16 | Male | 27 | 3 | IV B | Subcutaneous panniculitis like T‐cell lymphoma | 12 | 12 | 8 cycles of chidamide+CHOEP | CR |
| C18 | Male | 55 | 1 | II B | Extranodal NK/T cell lymphoma, nasal type | 10 | 4 | 4 cycles of SMILE+radiation | PD |
| C20 | Female | 38 | 2 | II B | Extranodal NK/T cell lymphoma, nasal type | 15 | 15 | 6 cycles of GDP/ML+radiation | PR |
CHOEP, CHOP plus etoposide; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CR, complete remission.; GDP/ML, gemcitabine, dexamethasone, cisplatin, methotrexate, L‐asparaginase; PD, progressive disease; PR, partial remission; SMILE, steroid, methotrexate, ifosfamide, L‐asparaginase, and etoposide.